Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Synercid Aventis.

¹Università degli Studi, Dipartimento di Biologia, Sez di Fisiologia Generale, Via L Borsari 46 44100 Ferrara, Italy. clm@dns.unife.it

Current Opinion in Investigational Drugs (London, England : 2000)

|March 16, 2001

Summary

Synercid, a combination of quinupristin and dalfopristin, treats Gram-positive bacterial infections. Approved in 1999, it targets serious infections like pneumonia and skin issues, particularly those caused by Enterococcus faecium.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Adenosine enhances acetylcholine receptor channel openings and intracellular calcium 'spiking' in mouse skeletal myotubes.

Acta physiologica (Oxford, England)·2015

Same author

Betamethasone, progesterone and RU-486 (mifepristone) exert similar effects on connexin expression in trophoblast-derived HTR-8/SVneo cells.

Reproduction, fertility, and development·2011

Same author

Use of glucocorticoids in pregnancy.

Current pharmaceutical design·2010

Same author

cAMP efflux from human trophoblast cell lines: a role for multidrug resistance protein (MRP)1 transporter.

Molecular human reproduction·2010

Same author

Molecular mechanism involved in the transport of a prodrug dopamine glycosyl conjugate.

International journal of pharmaceutics·2006

Same author

Nuclear retinoic acid receptor beta as a tool in chemoprevention trials.

Current medicinal chemistry·2006

Area of Science:

Pharmacology
Infectious Diseases
Bacteriology

Background:

Rhône-Poulenc Rorer (RPR) developed Synercid (quinupristin/dalfopristin) as an injectable treatment.
Synercid targets infections caused by Gram-positive anaerobic bacteria.

Purpose of the Study:

To provide an overview of Synercid's development, approval, and market launch.
To report initial sales predictions for Synercid.

Main Methods:

Review of regulatory approval dates and market launch information.
Inclusion of financial predictions from market analysts.

Main Results:

Synercid received UK approval in July 1999 for specific infections.
Launched in the UK and US in September 1999, with EU approval following in December 1999.
Sales predictions varied, with significant growth anticipated between 1999 and 2004.

Conclusions:

Synercid was established as a treatment option for serious Gram-positive bacterial infections.
Market analysts projected substantial sales growth in the early 2000s.

Related Experiment Videos